Cargando…
Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan
BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line the...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/ https://www.ncbi.nlm.nih.gov/pubmed/25887125 http://dx.doi.org/10.1186/s12894-015-0027-4 |
_version_ | 1782369328516038656 |
---|---|
author | Koie, Takuya Ohyama, Chikara Yoneyama, Takahiro Yamamoto, Hayato Imai, Atsushi Hatakeyama, Shingo Hashimoto, Yasuhiro Yoneyama, Tohru Tobisawa, Yuki Mori, Kazuyuki |
author_facet | Koie, Takuya Ohyama, Chikara Yoneyama, Takahiro Yamamoto, Hayato Imai, Atsushi Hatakeyama, Shingo Hashimoto, Yasuhiro Yoneyama, Tohru Tobisawa, Yuki Mori, Kazuyuki |
author_sort | Koie, Takuya |
collection | PubMed |
description | BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced RCC or mRCC. METHODS: In this retrospective study, we focused on eighteen patients who underwent first-line therapy with axitinib between May 2012 and May 2014 at Hirosaki University. Axitinib was orally administered at a dose of 10 mg daily. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included overall response rate (ORR) and adverse events (AEs). RESULTS: All patients had histologically proven clear cell RCC. The median duration of the administration of axitinib was 10.8 months. According to the response evaluation criteria for solid tumors, five patients (27.8%) achieved a partial response and nine (50%) had stable disease. The 1-year PFS rate was 84.4%, and the median PFS was 20.4 months (95% confidence interval, 17.5 – 21.7). No serious AEs were reported during the study, and there were no toxicity-related deaths. CONCLUSIONS: In the current study, axitinib showed acceptable oncological outcomes and favorable safety profile as first-line therapy for locally advanced RCC or mRCC in treatment-naïve Japanese patients. Thus, first-line therapy with axitinib may provide a feasible option for treatment of advanced RCC or mRCC patients. |
format | Online Article Text |
id | pubmed-4417199 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44171992015-05-03 Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan Koie, Takuya Ohyama, Chikara Yoneyama, Takahiro Yamamoto, Hayato Imai, Atsushi Hatakeyama, Shingo Hashimoto, Yasuhiro Yoneyama, Tohru Tobisawa, Yuki Mori, Kazuyuki BMC Urol Research Article BACKGROUND: Clinical benefit of axitinib as a first line agent to treat patients with metastatic renal cell carcinoma (mRCC), or locally advanced renal cell carcinoma (RCC) have not been clearly demonstrated. The aim of this study was to evaluate the efficacy and safety of axitinib as first-line therapy in Japanese patients with locally advanced RCC or mRCC. METHODS: In this retrospective study, we focused on eighteen patients who underwent first-line therapy with axitinib between May 2012 and May 2014 at Hirosaki University. Axitinib was orally administered at a dose of 10 mg daily. Progression-free survival (PFS) was the primary endpoint, while secondary endpoints included overall response rate (ORR) and adverse events (AEs). RESULTS: All patients had histologically proven clear cell RCC. The median duration of the administration of axitinib was 10.8 months. According to the response evaluation criteria for solid tumors, five patients (27.8%) achieved a partial response and nine (50%) had stable disease. The 1-year PFS rate was 84.4%, and the median PFS was 20.4 months (95% confidence interval, 17.5 – 21.7). No serious AEs were reported during the study, and there were no toxicity-related deaths. CONCLUSIONS: In the current study, axitinib showed acceptable oncological outcomes and favorable safety profile as first-line therapy for locally advanced RCC or mRCC in treatment-naïve Japanese patients. Thus, first-line therapy with axitinib may provide a feasible option for treatment of advanced RCC or mRCC patients. BioMed Central 2015-04-16 /pmc/articles/PMC4417199/ /pubmed/25887125 http://dx.doi.org/10.1186/s12894-015-0027-4 Text en © Koie et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Article Koie, Takuya Ohyama, Chikara Yoneyama, Takahiro Yamamoto, Hayato Imai, Atsushi Hatakeyama, Shingo Hashimoto, Yasuhiro Yoneyama, Tohru Tobisawa, Yuki Mori, Kazuyuki Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title | Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title_full | Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title_fullStr | Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title_full_unstemmed | Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title_short | Feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in Japan |
title_sort | feasibly of axitinib as first-line therapy for advanced or metastatic renal cell carcinoma: a single-institution experience in japan |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4417199/ https://www.ncbi.nlm.nih.gov/pubmed/25887125 http://dx.doi.org/10.1186/s12894-015-0027-4 |
work_keys_str_mv | AT koietakuya feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT ohyamachikara feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT yoneyamatakahiro feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT yamamotohayato feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT imaiatsushi feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT hatakeyamashingo feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT hashimotoyasuhiro feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT yoneyamatohru feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT tobisawayuki feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan AT morikazuyuki feasiblyofaxitinibasfirstlinetherapyforadvancedormetastaticrenalcellcarcinomaasingleinstitutionexperienceinjapan |